scispace - formally typeset
Search or ask a question
Institution

Aix-Marseille University

EducationMarseille, France
About: Aix-Marseille University is a education organization based out in Marseille, France. It is known for research contribution in the topics: Population & Galaxy. The organization has 24326 authors who have published 54240 publications receiving 1455416 citations. The organization is also known as: University Aix-Marseille & université d'Aix-Marseille.


Papers
More filters
Journal ArticleDOI
05 Nov 2015-Cell
TL;DR: It is shown that Snf7, the main component of ESCRT-III, polymerizes into spirals at the surface of lipid bilayers, and it is observed that the elastic expansion of compressed Snf 7 spirals generated an area difference between the two sides of the membrane and thus curvature.

275 citations

Journal ArticleDOI
TL;DR: The main features of ICI–ILD are reported with a focus on clinical presentation, radiological patterns and therapeutic strategies, and oncologists need to diagnose and adequately treat this adverse event.
Abstract: Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event.Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI-ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies.We identified 64 (3.5%) out of 1826 cancer patients with ICI-ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2-27.4) months. Onset tended to occur earlier in lung cancer versus melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7-73.8%).ICI-ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event.

275 citations

Journal ArticleDOI
Georges Aad1, Brad Abbott2, Jalal Abdallah3, S. Abdel Khalek4  +2868 moreInstitutions (187)
TL;DR: In this paper, an improved measurement of the mass of the Higgs boson is derived from a combined fit to the reconstructed invariant mass spectra of the decay channels H -> gamma gamma and H -> ZZ* -> 4l.
Abstract: An improved measurement of the mass of the Higgs boson is derived from a combined fit to the reconstructed invariant mass spectra of the decay channels H -> gamma gamma and H -> ZZ* -> 4l. The analysis uses the pp collision data sample recorded by the ATLAS experiment at the CERN Large Hadron Collider at center-of-mass energies of 7 TeV and 8 TeV, corresponding to an integrated luminosity of 25 fb(-1). The measured value of the Higgs boson mass is m(H) = 125.36 +/- 0.37(stat) +/- 0.18 (syst) GeV. This result is based on improved energy-scale calibrations for photons, electrons, and muons as well as other analysis improvements, and supersedes the previous result from ATLAS. Upper limits on the total width of the Higgs boson are derived from fits to the invariant mass spectra of the H -> gamma gamma and H -> ZZ* -> 4l decay channels.

274 citations

Journal ArticleDOI
TL;DR: Previous epidemiological studies have demonstrated a high prevalence of cardiovascular risk factors in psoriasis patients, including metabolic syndrome, cigarette smoking, obesity, hypertension, diabetes mellitus, insulin resistance and dyslipidaemia.
Abstract: Previous epidemiological studies have demonstrated a high prevalence of cardiovascular (CV) risk factors in psoriasis patients, including metabolic syndrome, cigarette smoking, obesity, hypertension, diabetes mellitus, insulin resistance and dyslipidaemia. An increase in CV morbidity and mortality attributable to psoriasis is still under question. Primary objective: to assess CV morbidity and mortality in psoriasis and psoriatic arthritis (PsA) including stroke, coronary artery disease, myocardial infarction (MI) and peripheral artery disease. Secondary objectives: to assess if psoriasis per se is an independent CV risk factor and if psoriasis severity is a predictor of CV risk. We also evaluated the effect of conventional systemic treatments for psoriasis on CV mortality. A systematic literature search was carried out from 1980 to December 2011, in the Embase, Medline and Cochrane Library databases, in English and French using a combination of keywords including (Psoriasis) OR (Psoriatic arthritis) AND (Myocardial infarction) OR (Coronaropathy) OR (Stroke) OR (Cardiovascular) AND (Methotrexate) AND (Ciclosporin) AND (Retinoids). Of the 929 identified references, 33 observational studies evaluating the rates of cardiovascular events (CVE) in patients with psoriasis and PsA compared with controls were selected. Meta-analysis of both cohort and cross-sectional studies showed an increased risk of MI with Odds Ratio (OR) of 1.25 (95% CI 1.03–1.52) and 1.57 (95% CI 1.08–2.27) in psoriasis and PsA, respectively, compared with the general population. The risk of MI was more pronounced for patients having severe psoriasis and for patients with psoriasis of early onset. It remained significantly elevated after controlling for major CV risk factors. The meta-analysis identified a small, but significant association between psoriasis, PsA and coronary artery disease with an OR between 1.19 (95% CI 1.14–1.24) for cross-sectional studies, 1.20 (95% CI 1.13–1.27) for cohort studies and 1.84 (95% CI 1.09–3.09) for case–control studies. The risk of coronary artery disease seemed to be more pronounced in patients with severe psoriasis and in patients with psoriasis of early onset. The meta-analysis assessing the risk of stroke gave inconclusive results: analysis of cross-sectional studies suggested that psoriasis patients had a slightly higher risk of stroke with an OR of 1.14 (95% CI 1.08–1.99), whereas the meta-analysis of cohort studies failed to show an association. There was also an increased risk of peripheral artery disease in psoriasis. No significant increased risk of CV mortality could be shown for both psoriasis and PsA patients. The use of methotrexate was associated with a reduced incidence of cardiovascular disease in two studies. The use of etretinate was associated with a reduction of CV mortality in one study. Potential selection bias such as the ‘healthy user effect’ prevents from drawing definite conclusions. There may be a small, but significant increased risk of CVE, but not of CV mortality in psoriasis and PsA patients. The psoriasis attributable risk remains difficult to assess due to confounding factors. The moderate quality of CV risk factors reporting in studies should be acknowledged. In addition, heterogeneity in study design, outcome definition and assessment represent major limitations. Nevertheless, screening and management of CV risk factors are important in psoriasis.

274 citations

Journal ArticleDOI
TL;DR: Results indicate that cancer cell–derived MPs bearing PSGL-1 and TF play a key role in thrombus formation in vivo and targeting these MPs could be of clinical interest in the prevention of thrombosis and to limit formation of metastasis in cancer patients.
Abstract: Recent publications have demonstrated the presence of tissue factor (TF)–bearing microparticles (MPs) in the blood of patients suffering from cancer. However, whether these MPs are involved in thrombosis remains unknown. We show that pancreatic and lung cancer cells produce MPs that express active TF and P-selectin glycoprotein ligand 1 (PSGL-1). Cancer cell–derived MPs aggregate platelets via a TF-dependent pathway. In vivo, cancer cell–derived MPs, but not their parent cells, infused into a living mouse accumulate at the site of injury and reduce tail bleeding time and the time to occlusion of venules and arterioles. This thrombotic state is also observed in mice developing tumors. In such mice, the amount of circulating platelet-, endothelial cell–, and cancer cell–derived MPs is increased. Endogenous cancer cell–derived MPs shed from the growing tumor are able to accumulate at the site of injury. Infusion of a blocking P-selectin antibody abolishes the thrombotic state observed after injection of MPs or in mice developing a tumor. Collectively, our results indicate that cancer cell–derived MPs bearing PSGL-1 and TF play a key role in thrombus formation in vivo. Targeting these MPs could be of clinical interest in the prevention of thrombosis and to limit formation of metastasis in cancer patients.

273 citations


Authors

Showing all 24784 results

NameH-indexPapersCitations
Didier Raoult1733267153016
Andrea Bocci1722402176461
Marc Humbert1491184100577
Carlo Rovelli1461502103550
Marc Besancon1431799106869
Jian Yang1421818111166
Josh Moss139101989255
Maksym Titov1391573128335
Bernard Henrissat139593100002
R. D. Kass1381920107907
Stylianos E. Antonarakis13874693605
Jean-Paul Kneib13880589287
Brad Abbott137156698604
Shu Li136100178390
Georges Aad135112188811
Network Information
Related Institutions (5)
University of Paris
174.1K papers, 5M citations

96% related

Pierre-and-Marie-Curie University
56.1K papers, 2.3M citations

94% related

Centre national de la recherche scientifique
382.4K papers, 13.6M citations

94% related

University of Geneva
65.2K papers, 2.9M citations

94% related

University of California, San Diego
204.5K papers, 12.3M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023170
2022748
20215,607
20205,697
20195,288
20185,125